PRKCD and neoplasm: These findings establish that germline modifications in immune regulatory genes can profoundly affect anti-tumor immunity and the efficacy of PD-1/PD-L1 blockade, as described previously, in the case of decreased expression/activity of PKCδ in myeloid lineage mediating improved anti-tumor immunity by altering the M1/M2 ratio.